Inhibition of morphine tolerance by NMDA receptor antagonists in the formalin test

Kabirullah Lutfy, Ke-Zhong Shen, Richard M. Woodward, Eckard Weber

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

5-Nitro-6,7-dimethyl-1,4-dihydro-2,3-quinoxalinedione (ACEA-1328) was characterized in vitro for antagonism of excitatory amino acid receptors, and subsequently tested in vivo and compared with MK-801 for phencyclidine (PCP)-like motor stimulation, antinociception, and effects on morphine tolerance in mice. Assayed on rat cerebral cortical glutamate receptors expressed in Xenopus oocytes ACEA-1328 showed potent (K(b) ~ 40 nM) antagonism at NMDA receptor/glycine sites and moderate (K(b) ~ 3 μM) antagonism at non-NMDA receptors. In both cases inhibition was predominantly competitive. ACEA-1328 was weak, or inactive, at NMDA receptor glutamate recognition sites, metabotropic receptors and opioid binding sites. In the formalin and rotarod tests ACEA-1328 and MK-801 produced both antinociception and disturbances of motor coordination. MK-801 caused a PCP-like motor stimulatory effect, whereas ACEA-1328 was devoid of such an effect. In tolerance studies, ACEA-1328 and MK-801 each blocked morphine tolerance in the formalin test, the effect of ACEA-1328 was dose-dependent. Our data contribute to a growing body of evidence which suggests that activation of NMDA receptors is critical for the development of opioid tolerance, and that antagonism at NMDA receptor/glycine sites may have potential as a means of diminishing tolerance with no PCP-like motor stimulatory side effects.

Original languageEnglish (US)
Pages (from-to)171-181
Number of pages11
JournalBrain Research
Volume731
Issue number1-2
DOIs
StatePublished - Aug 26 1996

Fingerprint

Pain Measurement
N-Methyl-D-Aspartate Receptors
Morphine
Dizocilpine Maleate
Glutamate Receptors
Glycine
Rotarod Performance Test
Phencyclidine
ACEA 1328
Opioid Receptors
Xenopus
Opioid Analgesics
Oocytes
Glutamic Acid
Binding Sites

Keywords

  • Antinociception
  • Formalin test
  • Glycine co-agonist site
  • NMDA receptor
  • Tolerance

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Inhibition of morphine tolerance by NMDA receptor antagonists in the formalin test. / Lutfy, Kabirullah; Shen, Ke-Zhong; Woodward, Richard M.; Weber, Eckard.

In: Brain Research, Vol. 731, No. 1-2, 26.08.1996, p. 171-181.

Research output: Contribution to journalArticle

Lutfy, Kabirullah ; Shen, Ke-Zhong ; Woodward, Richard M. ; Weber, Eckard. / Inhibition of morphine tolerance by NMDA receptor antagonists in the formalin test. In: Brain Research. 1996 ; Vol. 731, No. 1-2. pp. 171-181.
@article{db9765c189ae4b438e570b3087efb76b,
title = "Inhibition of morphine tolerance by NMDA receptor antagonists in the formalin test",
abstract = "5-Nitro-6,7-dimethyl-1,4-dihydro-2,3-quinoxalinedione (ACEA-1328) was characterized in vitro for antagonism of excitatory amino acid receptors, and subsequently tested in vivo and compared with MK-801 for phencyclidine (PCP)-like motor stimulation, antinociception, and effects on morphine tolerance in mice. Assayed on rat cerebral cortical glutamate receptors expressed in Xenopus oocytes ACEA-1328 showed potent (K(b) ~ 40 nM) antagonism at NMDA receptor/glycine sites and moderate (K(b) ~ 3 μM) antagonism at non-NMDA receptors. In both cases inhibition was predominantly competitive. ACEA-1328 was weak, or inactive, at NMDA receptor glutamate recognition sites, metabotropic receptors and opioid binding sites. In the formalin and rotarod tests ACEA-1328 and MK-801 produced both antinociception and disturbances of motor coordination. MK-801 caused a PCP-like motor stimulatory effect, whereas ACEA-1328 was devoid of such an effect. In tolerance studies, ACEA-1328 and MK-801 each blocked morphine tolerance in the formalin test, the effect of ACEA-1328 was dose-dependent. Our data contribute to a growing body of evidence which suggests that activation of NMDA receptors is critical for the development of opioid tolerance, and that antagonism at NMDA receptor/glycine sites may have potential as a means of diminishing tolerance with no PCP-like motor stimulatory side effects.",
keywords = "Antinociception, Formalin test, Glycine co-agonist site, NMDA receptor, Tolerance",
author = "Kabirullah Lutfy and Ke-Zhong Shen and Woodward, {Richard M.} and Eckard Weber",
year = "1996",
month = "8",
day = "26",
doi = "10.1016/S0006-8993(96)00469-6",
language = "English (US)",
volume = "731",
pages = "171--181",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Inhibition of morphine tolerance by NMDA receptor antagonists in the formalin test

AU - Lutfy, Kabirullah

AU - Shen, Ke-Zhong

AU - Woodward, Richard M.

AU - Weber, Eckard

PY - 1996/8/26

Y1 - 1996/8/26

N2 - 5-Nitro-6,7-dimethyl-1,4-dihydro-2,3-quinoxalinedione (ACEA-1328) was characterized in vitro for antagonism of excitatory amino acid receptors, and subsequently tested in vivo and compared with MK-801 for phencyclidine (PCP)-like motor stimulation, antinociception, and effects on morphine tolerance in mice. Assayed on rat cerebral cortical glutamate receptors expressed in Xenopus oocytes ACEA-1328 showed potent (K(b) ~ 40 nM) antagonism at NMDA receptor/glycine sites and moderate (K(b) ~ 3 μM) antagonism at non-NMDA receptors. In both cases inhibition was predominantly competitive. ACEA-1328 was weak, or inactive, at NMDA receptor glutamate recognition sites, metabotropic receptors and opioid binding sites. In the formalin and rotarod tests ACEA-1328 and MK-801 produced both antinociception and disturbances of motor coordination. MK-801 caused a PCP-like motor stimulatory effect, whereas ACEA-1328 was devoid of such an effect. In tolerance studies, ACEA-1328 and MK-801 each blocked morphine tolerance in the formalin test, the effect of ACEA-1328 was dose-dependent. Our data contribute to a growing body of evidence which suggests that activation of NMDA receptors is critical for the development of opioid tolerance, and that antagonism at NMDA receptor/glycine sites may have potential as a means of diminishing tolerance with no PCP-like motor stimulatory side effects.

AB - 5-Nitro-6,7-dimethyl-1,4-dihydro-2,3-quinoxalinedione (ACEA-1328) was characterized in vitro for antagonism of excitatory amino acid receptors, and subsequently tested in vivo and compared with MK-801 for phencyclidine (PCP)-like motor stimulation, antinociception, and effects on morphine tolerance in mice. Assayed on rat cerebral cortical glutamate receptors expressed in Xenopus oocytes ACEA-1328 showed potent (K(b) ~ 40 nM) antagonism at NMDA receptor/glycine sites and moderate (K(b) ~ 3 μM) antagonism at non-NMDA receptors. In both cases inhibition was predominantly competitive. ACEA-1328 was weak, or inactive, at NMDA receptor glutamate recognition sites, metabotropic receptors and opioid binding sites. In the formalin and rotarod tests ACEA-1328 and MK-801 produced both antinociception and disturbances of motor coordination. MK-801 caused a PCP-like motor stimulatory effect, whereas ACEA-1328 was devoid of such an effect. In tolerance studies, ACEA-1328 and MK-801 each blocked morphine tolerance in the formalin test, the effect of ACEA-1328 was dose-dependent. Our data contribute to a growing body of evidence which suggests that activation of NMDA receptors is critical for the development of opioid tolerance, and that antagonism at NMDA receptor/glycine sites may have potential as a means of diminishing tolerance with no PCP-like motor stimulatory side effects.

KW - Antinociception

KW - Formalin test

KW - Glycine co-agonist site

KW - NMDA receptor

KW - Tolerance

UR - http://www.scopus.com/inward/record.url?scp=0030603088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030603088&partnerID=8YFLogxK

U2 - 10.1016/S0006-8993(96)00469-6

DO - 10.1016/S0006-8993(96)00469-6

M3 - Article

C2 - 8883867

AN - SCOPUS:0030603088

VL - 731

SP - 171

EP - 181

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1-2

ER -